CLINICAL RECOMMENDATIONS |
|
Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment (clinical guidelines for therapists, third version)
|
7-43 |
ORIGINAL STUDIES |
|
Geyvandova T.V., Rogova S.Sh.
Obesity, non-alcoholic fatty liver disease, and FTO oligonucleotide polymorphism
|
44-49 |
|
Kozlova I.V., Kudishina M.M., Bykova A.P., Krylova Yu.S.
Pathology of the musculoskeletal system in inflammatory bowel diseases
|
50-57 |
|
Koroy P.V., Kravchenko Yu.A., Yagoda A.V.
Family of selectins in non-alcoholic fatty liver disease
|
58-63 |
|
Levitan B.N., Kasyanova T.R., Voloshina O.A., Martynova A.D.
Predictive value of studying lipopolysaccharide – binding protein in liver cirrhosis
|
64-70 |
|
Mukhtarova A.V., Batyushin M.M., Sinelnik E.S., Antipova N.V., Gadaborsheva H.Z.
Influence of TGF-β1 expression on the development of tubulointerstitial fibrosis in patients with primary chronic glomerulonephritis
|
71-76 |
|
Pavlenko V.V., Pavlenko A.F., Kazakova L.M.
Insulin-like growth factor IGF-I and bone metabolism in Crohn’s disease
|
77-81 |
|
Saneeva G.A.
Musculoskeletal manifestations and prevalence of orthopedic pathology: clinical and diagnostic significance in case of joint hypermobility syndrome
|
82-87 |
|
Tkachev A.V., Belovolova R.A., Mkrtchyan L.S., Mazovka K.E.
General patterns and regional features of epidemiology and the course of ulcerative colitis in the Rostov region
|
88-94 |
|
Pereverzeva K.G., Yakushin S.S.
Estimation of the efficacy and safety of using the system of remote monitoring of patients after myocardial infarction
|
95-103 |
REVIEWS |
|
Shorina D.A., Osadchuk M.A., Lazareva A.E., Vasilieva I.N.
Irritable bowel syndrome in combination with functional dyspepsia: features of the course and prognosis of outcomes
|
104-111 |
|
Osadchuk A.M., Osadchuk M.M., Zolotovskaya I.A.
Thrombotic complications in patients with liver cirrosis: current state of the problem
|
112-117 |
|
Kuznetsova A.S., Genkel V.V., Dolgushina A.I., Shaposhnik I.I, Olevskaya E.R., Selyanina A.A., Khusainova G.M.
Non-alcoholic fatty liver disease and atherosclerosis: common mechanisms of development and progression
|
118-125 |
|
Kostina N.E., Starodubtseva I.A., Sharapova Yu.A., Malyavin A.G.
Interstitial lung diseases, progressive phenotype: urgent problems of early diagnosis and early initiation of antifibrotic therapy
|
126-131 |
|
Tarasova L.V., Dimitrieva O.V., Dolgov I.Yu., Elmurzayeva A.A.
Models of risk determination of cancer-associated thromboses
|
132-137 |
GUIDELINES FOR PRACTITIONERS |
|
Yagoda A.V., Belotserkovskaya M.I., Gladkikh N.N., Ushakova O.V.
Systemic form of panniculitis with damage of internal organs
|
138-143 |
LECTURE |
|
Musaeva L.N., Esedov E.M., Abasova A.S., Mammaev S.N.
Melatonin metabolism in health and disease of the gastrointestinal tract (literature review)
|
144-151 |
|
Ponomareva E.Yu., Rebrov A.P.
Infective endocarditis in HIV-infected patients
|
152-158 |
ACTUAL ISSUES OF PHARMACOTHERAPY |
|
Pereverzev A.P., Ostroumova O.D.
Drug-induced hyperuricemia/gout. Part 2: certain medicines, the use of which is associated with an increased risk of developing of these diseases
|
159-169 |
Activities of RNMOT |
|
Digest events in SEPTEMBER 2021
|
170-177 |
JUBILEE |
|
To the 90th anniversary of professor A.V. Tuev
|
178-179 |
WE REMEMBER |
|
Andrey Apollonovich KIRICHENKO: August 4, 1950 — July 22, 2021 г.
|
180 |
Русский
